Another Potential Blockbuster for Johnson & Johnson Investors

A new class of diabetes drugs called SGLT-2 inhibitors -- which block the natural reabsorption of excess glucose in the bloodstream and allow it to pass out of the body -- could potentially be huge in the type 2 diabetes space, and Johnson & Johnson (JNJ 0.19%) recently received a 10-5 recommendation for approval for its SGLT-2 inhibitor Invokana from an FDA advisory committee. If approved, JNJ would be the first to market in the United States with this type of drug, which could be a nice win for the company.